PCAT14 and prostate carcinoma: A reduced expression of PCAT14 in prostate cancer was related to T stage (P = 0.005), N stage (P = 0.009), primary therapy outcome (P = 0.022), residual tumor (P < 0.001), Gleason score (P < 0.001), and age (P = 0.020) (Table 1, Figure 2).